Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognosis of patients with ascites after PleurX insertion: an observational study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Minimally invasive assessment of hepatic function in children with indocyanine green elimination: a validation study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Modified Marshall Score Predicts Mortality in Patients With Walled-off Pancreatic Necrosis Treated in an Intensive Care Unit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The cost of endoscopic treatment for walled-off pancreatic necrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To evaluate the safety of PleurX in cirrhotic patients with refractory ascites.

METHODS: We prospectively registered patients who received a PleurX catheter cirrhosis-associated refractory ascites at our department from July 2015 to November 2016. Our control group consisted of matched cirrhotic patients with refractory ascites treated with large volume paracentesis (LVP) and patients with malignant ascites treated with PleurX during the same period.

RESULTS: We included 25 patients with cirrhosis-related ascites (7 in PleurX group) and 17 with malignant ascites (14 in PleurX group). Of these, six patients had hepatocellular carcinoma and cirrhosis (5 in PleurX group). None were eligible for insertion of a TIPS or liver transplantation. The maximum duration of follow-up was (480 days) in the PleurX group and 366 days in the LVP group (median 84 and 173 days, respectively). There was no difference in mortality when comparing PleurX with LVP treatment (hazard ratios: 3.0 and 1.0, p = .23 and .96, respectively). Mortality was higher in patients with malignant ascites (p= .01). We found no significant differences in adverse events (incl. spontaneous bacterial peritonitis) or in P-albumin, P-creatinine and P-sodium between the groups.

CONCLUSION: PleurX insertion for the treatment of refractory ascites in cirrhotic patients appears to be safe. Prospective randomized trials are necessary in order to confirm these findings.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Gastroenterology
Vol/bind53
Udgave nummer3
Sider (fra-til)340-344
ISSN0036-5521
DOI
StatusUdgivet - mar. 2018

ID: 52668506